公开(公告)号：US20070196333A1

公开(公告)日：2007-08-23

申请号：US11360041

申请日：2006-02-23

申请人： Fu-Yung Lin ,  Chih-Ping Yang ,  Shir-Ly Huang ,  Ching-Yuan Lee

发明人： Fu-Yung Lin ,  Chih-Ping Yang ,  Shir-Ly Huang ,  Ching-Yuan Lee

IPC分类号： A61K38/21 ,  A61K9/14 ,  C12P21/04 ,  A61K9/48 ,  A61K9/20

CPC分类号： A61K38/212

摘要： A composition of human interferon-alpha (IFN-α) subtypes produced from human lymphoblastoid cells is disclosed. These purified IFN-α composition comprise higher specific activities and may be applied in the treatment of cancers, viruses, and immuno diseases.

摘要翻译： 公开了由人类淋巴母细胞细胞产生的人类干扰素-α（IFN-α）亚型的组合物。 这些纯化的IFN-α组合物包含较高的比活性，可用于治疗癌症，病毒和免疫疾病。

公开(公告)号：US20080138412A1

公开(公告)日：2008-06-12

申请号：US11634072

申请日：2006-12-06

申请人： Fu-Yung Lin ,  Fang-Hsiung Hsiao ,  Ya-Ching Chang Chien

发明人： Fu-Yung Lin ,  Fang-Hsiung Hsiao ,  Ya-Ching Chang Chien

IPC分类号： A61K9/22 ,  A61K31/517 ,  A61K9/00

CPC分类号： A61K31/517 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054

摘要： A sustained release alfuzosin hydrochloride formulation contains alfuzosin hydrochloride as about 1% to about 5% by weight of the formulation, hydrophilic polymers as about 35% to about 75% by weight of the formulation, hydrophobic polymers as about 10% to about 30% by weight of the formulation, disintegrating agents as 10% to 30% by weight of the formulation and a binder as about 2% to about 12% by weight of the formulation. The hydrophilic and hydrophobic polymers are used as the release-modulating agent to control the dissolution profile of the alfuzosin hydrochloride formulation so that the formulation releases alfuzosin hydrochloride slowly and continuously as the formulation passed through the gastrointestinal tract. The present invention also relates to a method for preparing the above formulation.

摘要翻译： 持续释放的阿夫唑嗪盐酸盐制剂含有盐酸阿夫唑嗪约占制剂重量的约1％至约5％，亲水性聚合物为制剂重量的约35％至约75％，疏水性聚合物为约10％至约30％ 制剂重量，崩解剂为制剂重量的10％至30％，粘合剂为制剂重量的约2％至约12％。 亲水和疏水聚合物用作释放调节剂以控制盐酸阿夫唑嗪的溶出曲线，使得当制剂通过胃肠道时，制剂缓慢且连续地释放盐酸阿夫唑嗪。 本发明还涉及制备上述配方的方法。